Resumes
Resumes
Chengzhen Ren Phones & Addresses
-
12601 Fall Branch Ln, Pearland, TX 77584
-
Houston, TX
-
Austin, TX
Business Records
Name / Title
Company / Classification
Phones & Addresses
Director, Managing
SUNNY ROCK INTERNATIONAL LLC
Nonclassifiable Establishments
Nonclassifiable Establishments
12601 Fall Br Ln, Pearland, TX 77584
5855 Sovereign Dr, Houston, TX 77036
5855 Sovereign Dr, Houston, TX 77036
Director, President
CLARESTONE INTERNATIONAL, LLC
Investor · Nonclassifiable Establishments
Investor · Nonclassifiable Establishments
8411 Mullins Dr, Houston, TX 77096
3910 Clarestone Dr, Pearland, TX 77584
3910 Clarestone Dr, Pearland, TX 77584
Publications
Us Patents
Rtvp Based Compositions And Methods For The Treatment Of Prostate Cancer
View pageUS Patent:
7645452, Jan 12, 2010
Filed:
Apr 17, 2003
Appl. No.:
10/417727
Inventors:
Timothy C. Thompson - Houston TX, US
Chengzhen Ren - Pearland TX, US
Chengzhen Ren - Pearland TX, US
Assignee:
Baylor College of Medicine - Houston TX
International Classification:
A61K 39/00
US Classification:
4241841, 514 2, 530350
Abstract:
This invention relates to a gene encoding RTVP that has been shown to be up-regulated by p53 using differential display-PCR and subsequently by co-transfection studies. RTVP-1 mRNA is abundant in normal mouse and human prostatic epithelial cells and primary tumors, but is significantly down regulated in metastatic mouse and human prostate cancer. In prostate cancer cells overexpression of the mouse RTVP-1 gene (mRTVP-1) induced apoptosis that was accompanied by increased caspase 8, 9 and 3 activities. mRTVP-1-stimulated apoptosis was also associated with increased levels of bax, bad and activated BID; reduced levels of bcl-2 and bcl-X; and cytosolic cytochrome c accumulation. Adenoviral-vector-mediated mRTVP-1 expression lead to potent growth suppression and antimetastatic activities in an orthotopic mouse model of prostate cancer in vivo. These therapeutic activities were associated with anti-angiogenic effects and importantly a local and systemic immune response. Accordingly, p53 was linked with suppression of metastasis through its induction of mRTVP-1, which can concurrently induce apoptosis, suppress angiogenesis and stimulate an antitumor immune response.
Rtvp-Glipr-Like Compositions And Methods For The Detection, Treatment And Prevention Of Prostate Cancer
View pageUS Patent:
7723475, May 25, 2010
Filed:
Aug 31, 2005
Appl. No.:
11/217067
Inventors:
Timothy C. Thompson - Houston TX, US
Chenghui Ren - Houston TX, US
Chengzhen Ren - Houston TX, US
Chenghui Ren - Houston TX, US
Chengzhen Ren - Houston TX, US
Assignee:
Baylor College of Medicine - Houston TX
International Classification:
C07K 14/00
A61K 38/00
A61K 38/00
US Classification:
530350, 514 2
Abstract:
The invention is directed to purified and isolated novel RGL2 polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
Rtvp Based Compositions And Methods For The Treatment Of Prostate Cancer
View pageUS Patent:
7824685, Nov 2, 2010
Filed:
Jan 19, 2005
Appl. No.:
11/038285
Inventors:
Timothy C. Thompson - Houston TX, US
Chengzhen Ren - Pearland TX, US
Chengzhen Ren - Pearland TX, US
Assignee:
Baylor College of Medicine - Houston TX
International Classification:
A61K 39/00
US Classification:
4241841, 514 2, 530350
Abstract:
This invention relates to a gene encoding RTVP that has been shown to be up-regulated by p53 using differential display-PCR and subsequently by co-transfection studies. RTVP-1 mRNA is abundant in normal mouse and human prostatic epithelial cells and primary tumors, but is significantly down regulated in metastatic mouse and human prostate cancer. In prostate cancer cells overexpression of the mouse RTVP-1 gene (mRTVP-1) induced apoptosis that was accompanied by increased caspase 8, 9 and 3 activities. mRTVP-1-stimulated apoptosis was also associated with increased levels of bax, bad and activated BID; reduced levels of bcl-2 and bcl-X; and cytosolic cytochrome c accumulation. Adenoviral-vector-mediated mRTVP-1 expression lead to potent growth suppression and antimetastatic activities in an orthotopic mouse model of prostate cancer in vivo. These therapeutic activities were associated with anti-angiogenic effects and importantly a local and systemic immune response. Accordingly, p53 was linked with suppression of metastasis through its induction of mRTVP-1, which can concurrently induce apoptosis, suppress angiogenesis and stimulate an antitumor immune response.
Rtvp Based Compositions And Methods For The Treatment Of Prostate Cancer
View pageUS Patent:
20020052025, May 2, 2002
Filed:
Jun 8, 2001
Appl. No.:
09/876225
Inventors:
Timothy Thompson - Houston TX, US
Chengzhen Ren - Pearland TX, US
Chengzhen Ren - Pearland TX, US
International Classification:
C12N009/99
C07H021/04
C12P021/02
C12N005/06
C07H021/04
C12P021/02
C12N005/06
US Classification:
435/069300, 435/325000, 435/320100, 536/023200, 435/184000
Abstract:
This invention relates to a gene encoding RTVP that has been shown to be up-regulated by p53 using differential display-PCR and subsequently by co-transfection studies. RTVP-1 mRNA is abundant in normal mouse and human prostatic epithelial cells and primary tumors, but is significantly down regulated in metastatic mouse and human prostate cancer. In prostate cancer cells overexpression of the mouse RTVP-1 gene (mRTVP-1) induced apoptosis that was accompanied by increased caspase 8, 9 and 3 activities. mRTVP-1-stimulated apoptosis was also associated with increased levels of bax, bad and activated BID; reduced levels of bcl-2 and bcl-X; and cytosolic cytochrome c accumulation. Adenoviral-vector-mediated mRTVP-1 expression lead to potent growth suppression and antimetastatic activities in an orthotopic mouse model of prostate cancer in vivo. These therapeutic activities were associated with anti-angiogenic effects and importantly a local and systemic immune response. Accordingly, p53 was linked with suppression of metastasis through its induction of mRTVP-1, which can concurrently induce apoptosis, suppress angiogenesis and stimulate an antitumor immune response. Thus, the invention includes compositions and methods, based on RTVP nucleic acid, polypeptides, and antibodies, for use in the treatment, prevention and detection of neoplastic disease and, specifically, metastatic prostatic neoplasia.
Composition And Method For The Treatment And Prevention Of Metastatic Disorders
View pageUS Patent:
20040018173, Jan 29, 2004
Filed:
Apr 7, 2003
Appl. No.:
10/408133
Inventors:
Timothy Thompson - Houston TX, US
Chengzhen Ren - Pearland TX, US
Chengzhen Ren - Pearland TX, US
Assignee:
Baylor College of Medicine - Houston TX
International Classification:
A61K048/00
C07H021/04
A61K038/44
C12N015/86
C07H021/04
A61K038/44
C12N015/86
US Classification:
424/093200, 424/094400, 435/456000, 435/320100, 435/325000, 536/023200
Abstract:
The invention relates to methods for the isolation of metastatic sequences and the isolated sequences. Cells from a cell line or an animal tissue are treated to form a cell line predisposed to cancer. Treated cells are implanted in an animal and incubated for a period of time sufficient for the cells to proliferate and develop malignant transplants. RNA from the malignant transplant and the primary tumor are analyzed by differential display polymerase chain reaction. Differentially expressed genes are cloned, reanalyzed, and sequenced. These genes and sequences can be used as probes in the diagnosis of neoplastic disorders, as probes to isolate metastatic sequences and as a therapeutic agent in the treatment of neoplastic disorders. The metastatic sequence may be a dominant metastatic sequence or a recessive metastatic sequence.
Rtvp-Glipr-Like Compositions And Methods For The Detection, Treatment And Prevention Of Prostate Cancer
View pageUS Patent:
20060240025, Oct 26, 2006
Filed:
Jun 8, 2004
Appl. No.:
10/559994
Inventors:
Timothy Thompson - Houston TX, US
Chenghui Ren - Houston TX, US
Chengzhen Ren - Pearland TX, US
Chenghui Ren - Houston TX, US
Chengzhen Ren - Pearland TX, US
International Classification:
C12Q 1/68
C07H 21/04
C12P 21/06
A61K 39/395
A61K 39/00
C07K 14/82
C07K 16/30
C07H 21/04
C12P 21/06
A61K 39/395
A61K 39/00
C07K 14/82
C07K 16/30
US Classification:
424155100, 435006000, 435069100, 435320100, 435325000, 530350000, 530388800, 424184100, 536023500
Abstract:
The invention is directed to purified and isolated novel RGL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.